Two new trials saw no impact of thrombolytics in reducing disability at 90 days, but some positive signals offer hope.

Two randomized trials found that intra-arterial urokinase and tenecteplase did not improve functional outcomes after ...

Open and endoscopic carpal-tunnel releases are commonly used as the definitive treatment for carpal tunnel syndrome. This ...

NDAQ:HUMA) Humacyte Provides Update on Commercial Launch and Pricing of Symvess(TM) (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma ...

Adding durvalumab and bevacizumab to transarterial chemoembolization improved responses and progression-free survival.

The ARIES-HM3 substudy may help persuade implanters who are less well-versed in the circulatory changes an LVAD affords.

Men vs women with spontaneous intracerebral hemorrhage (ICH) have a higher risk for deep bleeds but a lower risk for poor outcomes.

The backpacks heaped on the table at Glad Tidings Church in Hancock Sunday morning were a testament to the work the Hancock ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial ...

They may have multiple comorbidities and are often medically unstable; treatment must balance the need to prevent ischemic post-procedure complications against the risk that GI hemorrhage in the ...

Dr. Ali Krisht has spent a lifetime growing into the role of one of the world’s foremost authorities on neurosurgery — and he ...